Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution

Marilena Cesari, Franco Bertoni, Patrizia Bacchini, Mario Mercuri, Emanuela Palmerini, Stefano Ferrari

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: We analyzed clinical and treatment-related factors influencing the outcome of patients with mesenchymal chondrosarcoma (MC). Twenty-six patients (median age, 31 years) were identified using the Tumor Center and Chemotherapy Department database of the study institute. Methods: Patients received surgery (24 patients) and/or radiotherapy (5 patients), and chemotherapy (12 patients). Results: After a median follow-up of 48 months (7-237 months) 10 patients were alive. The 10-year overall survival (OS) was 27% in those who achieved complete surgical remission and 0% in those who did not (P = 0.0007). A worse 10-year probability of OS was observed in patients who were metastatic at presentation (metastatic 0%, localized 31%, P = 0.02), in patients with soft tissue MC (soft tissue MC 0%, bone MC 29%, P = 0.06) and in hemangiopericytoma-like MC (hemangiopericytoma-like MC 0%, Ewing's-like MC 33.5%, P = 0.9). In those patients who achieved complete surgical remission, the 10-year DFS was 76% for those who received chemotherapy and 17% for those who did not (P = 0.008). Conclusions: Our experience confirmed the importance of complete surgical remission in MC treatment and suggests that the addition of chemotherapy should offer a benefit in terms of DFS. Due to the rarity of MC, multicentrer studies are needed to identify the most active chemotherapy regimen.

Original languageEnglish
Pages (from-to)423-427
Number of pages5
JournalTumori
Volume93
Issue number5
Publication statusPublished - Sep 2007

Fingerprint

Mesenchymal Chondrosarcoma
Drug Therapy
Hemangiopericytoma
Survival
Radiotherapy

Keywords

  • Chemotherapy
  • Mesenchymal chondrosarcoma
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research

Cite this

Cesari, M., Bertoni, F., Bacchini, P., Mercuri, M., Palmerini, E., & Ferrari, S. (2007). Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori, 93(5), 423-427.

Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. / Cesari, Marilena; Bertoni, Franco; Bacchini, Patrizia; Mercuri, Mario; Palmerini, Emanuela; Ferrari, Stefano.

In: Tumori, Vol. 93, No. 5, 09.2007, p. 423-427.

Research output: Contribution to journalArticle

Cesari, M, Bertoni, F, Bacchini, P, Mercuri, M, Palmerini, E & Ferrari, S 2007, 'Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution', Tumori, vol. 93, no. 5, pp. 423-427.
Cesari M, Bertoni F, Bacchini P, Mercuri M, Palmerini E, Ferrari S. Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. Tumori. 2007 Sep;93(5):423-427.
Cesari, Marilena ; Bertoni, Franco ; Bacchini, Patrizia ; Mercuri, Mario ; Palmerini, Emanuela ; Ferrari, Stefano. / Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution. In: Tumori. 2007 ; Vol. 93, No. 5. pp. 423-427.
@article{2366c096fd9b48d9b87254dbe193d22a,
title = "Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution",
abstract = "Background: We analyzed clinical and treatment-related factors influencing the outcome of patients with mesenchymal chondrosarcoma (MC). Twenty-six patients (median age, 31 years) were identified using the Tumor Center and Chemotherapy Department database of the study institute. Methods: Patients received surgery (24 patients) and/or radiotherapy (5 patients), and chemotherapy (12 patients). Results: After a median follow-up of 48 months (7-237 months) 10 patients were alive. The 10-year overall survival (OS) was 27{\%} in those who achieved complete surgical remission and 0{\%} in those who did not (P = 0.0007). A worse 10-year probability of OS was observed in patients who were metastatic at presentation (metastatic 0{\%}, localized 31{\%}, P = 0.02), in patients with soft tissue MC (soft tissue MC 0{\%}, bone MC 29{\%}, P = 0.06) and in hemangiopericytoma-like MC (hemangiopericytoma-like MC 0{\%}, Ewing's-like MC 33.5{\%}, P = 0.9). In those patients who achieved complete surgical remission, the 10-year DFS was 76{\%} for those who received chemotherapy and 17{\%} for those who did not (P = 0.008). Conclusions: Our experience confirmed the importance of complete surgical remission in MC treatment and suggests that the addition of chemotherapy should offer a benefit in terms of DFS. Due to the rarity of MC, multicentrer studies are needed to identify the most active chemotherapy regimen.",
keywords = "Chemotherapy, Mesenchymal chondrosarcoma, Radiotherapy",
author = "Marilena Cesari and Franco Bertoni and Patrizia Bacchini and Mario Mercuri and Emanuela Palmerini and Stefano Ferrari",
year = "2007",
month = "9",
language = "English",
volume = "93",
pages = "423--427",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Mesenchymal chondrosarcoma. An analysis of patients treated at a single institution

AU - Cesari, Marilena

AU - Bertoni, Franco

AU - Bacchini, Patrizia

AU - Mercuri, Mario

AU - Palmerini, Emanuela

AU - Ferrari, Stefano

PY - 2007/9

Y1 - 2007/9

N2 - Background: We analyzed clinical and treatment-related factors influencing the outcome of patients with mesenchymal chondrosarcoma (MC). Twenty-six patients (median age, 31 years) were identified using the Tumor Center and Chemotherapy Department database of the study institute. Methods: Patients received surgery (24 patients) and/or radiotherapy (5 patients), and chemotherapy (12 patients). Results: After a median follow-up of 48 months (7-237 months) 10 patients were alive. The 10-year overall survival (OS) was 27% in those who achieved complete surgical remission and 0% in those who did not (P = 0.0007). A worse 10-year probability of OS was observed in patients who were metastatic at presentation (metastatic 0%, localized 31%, P = 0.02), in patients with soft tissue MC (soft tissue MC 0%, bone MC 29%, P = 0.06) and in hemangiopericytoma-like MC (hemangiopericytoma-like MC 0%, Ewing's-like MC 33.5%, P = 0.9). In those patients who achieved complete surgical remission, the 10-year DFS was 76% for those who received chemotherapy and 17% for those who did not (P = 0.008). Conclusions: Our experience confirmed the importance of complete surgical remission in MC treatment and suggests that the addition of chemotherapy should offer a benefit in terms of DFS. Due to the rarity of MC, multicentrer studies are needed to identify the most active chemotherapy regimen.

AB - Background: We analyzed clinical and treatment-related factors influencing the outcome of patients with mesenchymal chondrosarcoma (MC). Twenty-six patients (median age, 31 years) were identified using the Tumor Center and Chemotherapy Department database of the study institute. Methods: Patients received surgery (24 patients) and/or radiotherapy (5 patients), and chemotherapy (12 patients). Results: After a median follow-up of 48 months (7-237 months) 10 patients were alive. The 10-year overall survival (OS) was 27% in those who achieved complete surgical remission and 0% in those who did not (P = 0.0007). A worse 10-year probability of OS was observed in patients who were metastatic at presentation (metastatic 0%, localized 31%, P = 0.02), in patients with soft tissue MC (soft tissue MC 0%, bone MC 29%, P = 0.06) and in hemangiopericytoma-like MC (hemangiopericytoma-like MC 0%, Ewing's-like MC 33.5%, P = 0.9). In those patients who achieved complete surgical remission, the 10-year DFS was 76% for those who received chemotherapy and 17% for those who did not (P = 0.008). Conclusions: Our experience confirmed the importance of complete surgical remission in MC treatment and suggests that the addition of chemotherapy should offer a benefit in terms of DFS. Due to the rarity of MC, multicentrer studies are needed to identify the most active chemotherapy regimen.

KW - Chemotherapy

KW - Mesenchymal chondrosarcoma

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=36749002082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749002082&partnerID=8YFLogxK

M3 - Article

VL - 93

SP - 423

EP - 427

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -